Morepen Laboratories Ltd Q3 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/9fkwyd2k8evldphglzby4jal.pdf

Key Takeaways


The Profitability Inflection

Suri: "This is one area which the company was lacking and struggling and trying to find ways how do we increase our EBITDA and certainly the pressure was to increase our revenues on the gross because most of the expenses are fixed expenses, so we have been able to crack it."

API: The Export Engine Shifts Gears

Suri: "We started the year we have 310 Kilolitre capacity, but we are closing the year with almost 400 KL capacity so we have added almost 90 Kilolitre of capacity, which is showing up in our increase in the revenue."

Formulation: The Third Pillar Takes Shape

Suri: "In this quarter itself it has grown 40%, so next quarter it will grow almost 60%, so we are expecting that formulation business give or take one year here or there it will become Rs.500 Crores in the coming three years time."

Medical Devices & OTC: Steady Growth, Strategic Patience

Suri: "Dr. Morepen is a consumers darling so it is basically a market friendly product so it deserves its own IPO and it deserves its own freedom but once we resolve things at a corporate level then Dr. Morepen will come out on its own, raise its own capital and go for its own IPO."

Capacity, Capex & the Balance Sheet


Guidance & Commitments

CommitmentSpecificsTimeline
Blended EBITDA marginMaintain 12-13% regularly, adding 20-30 bps per quarterComing two years
PAT marginReach ~6% by year-end, double digits thereafterFY2026
Formulation revenueGrow to ₹500 Cr from ~₹230-240 Cr baseThree years
API capacity additionAdd 100 KL to current ~400 KL baseSix to nine months
Total API capacity additionAdd 250 KLNext 12 months
Segment mix shiftAPI share to decline from 60% to ~50%As devices and formulation outgrow
Capex + working capital outlay₹200-250 CrNext two to three years
Formulation growth60% growth next quarterQ4 FY24

Key Metrics

MetricQ3 FY24
Net revenue₹449 Cr, +28% YoY
EBITDA₹55 Cr, +151% YoY
EBITDA margin12.18%, vs 6.22% in Q3 FY23
Profit before tax₹44 Cr, +200% YoY
Profit after tax₹32 Cr, +256% YoY
PAT margin7.13%, vs 2.57% in Q3 FY23
EPS₹0.63, vs ₹0.18 in Q3 FY23
API revenue₹253 Cr, +20% YoY
API exports growth+31% YoY
Medical devices revenue growth+24% YoY
Formulation business revenue growth+40% YoY
OTC / Dr. Morepen revenue growth-3% YoY
Institutional business (Jan Aushadhi) revenue₹32 Cr, +196% YoY
Glucometers installed base1.12 Cr meters
API capacity~400 KL, up from 310 KL at start of year